populations by conventional and high throughput deep sequencing methods. Uncharacterized 23 mutations were phenotyped for drug resistance using recombinant viruses. Conventional 24 genotyping detected viral UL97 kinase substitution C607Y after ganciclovir treatment, a 25 transient subpopulation of UL54 polymerase L773V first detected 8 weeks after starting 26 foscarnet, and a subpopulation of UL54 codon 981-2 deletion 2 months after adding cidofovir. 27
Deep sequencing of the same serial specimens revealed the same UL54 mutants sooner, along 28 with a more complex evolution of known and newly recognized mutant subpopulations missed 29 by conventional sequencing. UL54 exonuclease substitutions D413N, K513R and C539G were 30 newly shown to confer ganciclovir-cidofovir resistance, while L773V was shown to confer 31 foscarnet resistance and add to the ganciclovir resistance conferred by UL97 C607Y. Increased 32
Introduction 37
Human cytomegalovirus (CMV) is a major viral opportunistic pathogen in T-cell 38 immunodeficient populations including those with AIDS, transplants and hematologic 39 malignancies, causing disease such as pneumonia, gastrointestinal disease and retinitis. 40
Prevention of CMV morbidity and mortality has been largely successful over the past two 41 decades using ganciclovir or its oral prodrug valganciclovir in a prophylaxis or pre-emptive 42 treatment strategy designed to prevent active systemic viral infection or to suppress it promptly 43 upon reactivation (1) . In a minority of cases, the strategy fails when antiviral therapy is 44 insufficient to shut off viral replication in the presence of adverse host factors. Over time, this 45 may result in the accumulation of drug resistance mutations that eventually confer resistance to 46 all licensed anti-CMV drugs including foscarnet and cidofovir, which have the same CMV DNA 47 polymerase target. 48
Because viral isolation in cell culture is uncommon in current diagnostic laboratory 49 practice, and susceptibility testing of clinical CMV isolates lacks timely availability, genotypic 50 testing has become the usual means for detecting drug resistance and the basis for selection of 51 alternative therapy. This relies on the PCR amplification and sequencing of viral DNA from 52 clinical specimens, representing portions of the viral UL97 kinase gene involved in the initial 53 phosphorylation of ganciclovir, and the UL54 DNA polymerase gene (2). Seven common UL97 54 kinase amino acid substitutions (M460V/I, H520Q, C592G, A594V, L595S and C603W) are the 55 basis for diagnosing ganciclovir resistance in a large majority of cases, but less common UL97 56 mutations clustered at codons 590-607 can sometimes be involved. UL54 mutations tend to 57 evolve after more extensive drug exposure, and commonly confer varying levels of cross-58 resistance to other CMV antivirals (2). (4, 5). When focused on gene regions involved in drug resistance, it provides a cost-effective 67 approach to deep sequencing whereby a targeted codon range is covered hundreds or thousands 68 of times so that small variant subpopulations can be detected, as we recently showed for CMV 69 (6). This may improve the detection of emerging drug resistance. The objective of the current 70 study was to use this technology retrospectively to assess the resistance mutations that developed 71 over time in a case of CMV disease with high accompanying viral loads that responded only 72 transiently to various alternative antiviral treatments. 73
74

Case Report 75
This was a 54 year old male with a diagnosis of B-cell chronic lymphocytic leukemia 76 (CLL) made 11 years earlier and treated with 6 cycles of cyclophosphamide, fludarabine, 77 alemtuzumab and rituximab (CFAR), leading to partial remission. Seven years after initial 78 diagnosis, a matched unrelated donor stem cell transplant was unsuccessful, resulting in 79 persistent lymphopenia followed by frank CLL relapse, which was treated again with monthly 80 cycles of CFAR. After the second cycle, a peripheral plasma CMV load of 880 IU/mL was 81 detected and valganciclovir pre-emptive therapy was given for one month. A month after the 82 on December 31, 2017 by guest http://aac.asm.org/ Downloaded from 5 third cycle, the viral load rose to 2 x 10 4 IU/mL and another month of valganciclovir was given. 83 A fourth and delayed CFAR cycle was then given. Five weeks later, the plasma CMV load was 84 1.6 x 10 5 IU/mL while on valganciclovir. Two weeks later, the patient was admitted for fever and 85 hypoxemia. This is the zero point of the timeline shown in Figure 1 , where serial data on viral 86 loads, genotypes and therapy are shown. Drug resistant virus was suspected and therapy was 87 switched to intravenous foscarnet and immune globulin for possible CMV pneumonia. This 88 resulted in worse hypoxemia and pulmonary infiltrates attributed to fluid overload. A 89 bronchoscopy was positive only for Pneumocystis, which was treated with trimethoprim-90 sulfamethoxazole, whereas a shell vial culture for CMV was negative. Over the next several 91 weeks while on full dose (90 mg/kg twice daily) foscarnet, pulmonary infiltrates gradually 92 resolved. After 6 weeks, foscarnet dosing was reduced to once daily, and valganciclovir was 93 resumed at treatment doses. At week 8, the patient was readmitted for diffuse pneumonia; a 94 bronchoscopy with biopsy showed widespread presence of CMV inclusion bodies and no 95
Pneumocystis. Resumption of twice daily foscarnet was poorly tolerated because of pulmonary 96 edema, hypoxemia and electrolyte abnormalities. With rising plasma viral loads, therapy was 97 switched to high dose intravenous ganciclovir (10 mg/kg twice daily adjusted for renal function) 98 in combination with intravenous cidofovir (5 mg/kg weekly). Over the next several weeks the 99 pneumonia stabilized and improved. Cidofovir dosing was reduced to every two weeks, and the 100 patient was discharged on valganciclovir. The plasma viral load then started rising sharply. The 101 relapsed CLL remained evident, with a total T lymphocyte count <100/µL, but ongoing CMV 102 infection was felt to exclude further chemotherapy or marrow transplantation. to determine CMV loads as described (7). Amounts of these extracts (1-15 µL) estimated to 113 contain >2000 copies of viral DNA were amplified in nested PCRs to produce sequencing 114 templates for dideoxy sequencing (BigDye v.3, Applied Biosystems) of UL97 kinase codons 115 375-650 and UL54 DNA polymerase codons 300-1000. Sequences were compared with the 116 AD169 reference sequence for variants affecting amino acid encoding. High throughput deep 117 sequencing was performed on the original DNA genotyping extracts stored at 4C, and later on 118 fresh extracts of plasma specimens stored at -80C. For the fresh extracts, DNA was extracted 119 from 100 µL of plasma using the EZ1 Virus mini kit v2.0 on the EZ1 Advanced XL platform 120 (both from Qiagen, Germantown, MD) and eluted in 60 µL buffer AVE containing carrier RNA. 121
Sequencing was performed using the Roche 454 GS jr pyrosequencing platform as recently 122 published (6). After an initial long range PCR to amplify ~2 kb and ~4 kb targets for UL97 and 123 UL54 respectively, the PCR products were used as templates for further amplification using 124 primers specific for overlapping ~350 bp segments of the CMV target sequence and 125 incorporating 454 adapter sequences and barcodes specific to individual specimens. This 126 sequencing library preparation stage was multiplexed across specimens and primers using the of foscarnet, after ~4 months of valganciclovir therapy, already showed the full development of 144 UL97 amino acid substitution C607Y, one of the less common ganciclovir resistance mutations 145 (9), along with the known UL97 polymorphism D605E (10). These findings persisted through all 146 subsequent genotypic assays (Fig. 1) . At week 8, a partial ~30% subpopulation of UL54 147 substitution L773V was detected. This mutation was previously observed under foscarnet in cell 148 culture but its phenotype was not confirmed by transfer into a baseline virus (11). It was re-149 detected twice during and immediately after stopping foscarnet, but not later at week 16 and UL54 S655L, N685S and N898D relative to reference strain AD169. At week 10, resistance-159 related subpopulations of UL54 L773V (51%), A809V (20%) and Q578H (6%) were detected. 160
At week 16, after stopping foscarnet, L773V had decreased in abundance, but many other known 161 and probable resistance mutations were noted to be evolving (Table 1) , none of which had been 162 detected by conventional genotyping. Four weeks later, L773V and A809V were absent or 163 decreasing, but the diverse UL54 mutations known or suspected to confer ganciclovir-cidofovir 164 or triple drug resistance mostly increased in abundance. 165
To test the reproducibility of the deep sequencing data, the same clinical specimens, and 166 those from additional sampling dates, were independently extracted from frozen plasma, PCR 167 amplified and sequenced as described (6) (access array AA12, Table 1 ). In comparison with 168 AA10, there was good reproducibility of the detected resistance-related genotypes, including 169 most of the minor subpopulations. Low level findings in AA10 of Q578H, K513R and several 170 variants unrelated to drug resistance were not confirmed in AA12, whereas AA12 but not AA10 171 detected low levels of Q578L, V715M and V781I. The two sequencing runs provided 172 comparable depth of sequencing (Table 1) Given the patient's intolerance of additional foscarnet, treatment was switched to double-205 dose ganciclovir and cidofovir. Ganciclovir dose escalation is described in the current clinical 206 guideline for lower grade resistance mutations (1), which could apply to C607Y but perhaps less 207 so in the presence of UL54 mutation (Table 2) . After several weeks this treatment appeared to 208 improve the viral load ( Fig. 1) and clinical condition, but the loads again increased rapidly when 209 the double-dose ganciclovir was replaced by valganciclovir, and the cidofovir dose was reduced 210 to every other week and later stopped due to nephrotoxicity. The most notable difference 211 between conventional and newer sequencing technology was observed at this point, where the 212 conventional genotype showed only UL97 C607Y, whereas deep sequencing showed 213 exonuclease substitutions N408D and P522S known to confer ganciclovir-cidofovir resistance 214
(2), D413N, K513R and C539G later confirmed to do so, and two substitutions that confer triple-215 drug resistance (A834P and deletion of codons 981-2) (2). Thus, significant genotypic cidofovir 216 resistance was present but not detected conventionally. Further, the UL97 C607Y was gradually 217 being displaced by the canonical A594V substitution that confers higher level ganciclovir 218 resistance (Table 2) . 219
on December 31, 2017 by guest http://aac.asm.org/ Downloaded from 11 New recombinant phenotyping data generated for this study validated the UL54 L773V 220 amino acid substitution as conferring foscarnet resistance and previously undocumented low 221 grade ganciclovir and cidofovir cross-resistance. It was sufficiently growth-attenuating (Fig. 2)  222 to remain a subpopulation of no more than ~50%, fading more rapidly upon withdrawal of 223 foscarnet than the well-known A809V (2) (Fig. 1 Deep sequencing data were reproducible on repeated analysis of samples from the same 233 plasma specimens (Arrays 10 and 12, Table 1 ), except some low-level subpopulations in the 3-234 6% range. The resistance-related mutations detected at these low levels were compatible with the 235 antiviral treatment history. In plasma extracts stored under adverse conditions (AA10), there 236 were some other non-reproducible subpopulations detected that did not track across specimens 237 (Table 1, observed at low levels. Because our data pertain to a single patient and are narrowly focused on 246 UL97 and UL54, they cannot be directly compared to reports of multiple fluctuating baseline 247 CMV genotypes in vivo (4, 5). Known UL97 and UL54 baseline polymorphisms ( Table 1) Table 1 . Sequence variants shown in italics were not detected by standard sequencing. 328
Those in boxes were newly phenotyped (Table 2) ranged from 550 ± 46 to 582 ± 50 (10). The UL97 kinase K355del knockout mutant was used as a control for 336 severe growth impairment (17). 337 
